| Angioedemas, Hereditary
Ruconest vs Takhzyro
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Ruconest vs Takhzyro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTakhzyro has a higher rate of injection site reactions vs Ruconest based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Takhzyro but not Ruconest, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ruconest
Takhzyro
At A Glance
IV injection
As needed (up to 2 doses/24 hours)
C1 esterase inhibitor (recombinant)
SC injection
Every 2-4 weeks
Plasma kallikrein inhibitor
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary 50 U/kg IV (max 4200 U) by slow intravenous injection over approximately 5 minutes; a second dose at the same level may be given if symptoms persist; no more than 2 doses within 24 hours.
Angioedemas, Hereditary (adults and pediatric >=12 years) 300 mg SC every 2 weeks; every 4 weeks may be considered if well-controlled (e.g., attack free) for more than 6 months.
Angioedemas, Hereditary (pediatric 6 to <12 years) 150 mg SC every 2 weeks; every 4 weeks may be considered if well-controlled (e.g., attack free) for more than 6 months.
Angioedemas, Hereditary (pediatric 2 to <6 years) 150 mg SC every 4 weeks.
Contraindications
- History of allergy to rabbits or rabbit-derived products
- History of life-threatening immediate hypersensitivity reactions to C1 esterase inhibitor preparations, including anaphylaxis
—
Adverse Reactions
Most common (>=2%) Headache, nausea, diarrhea
Serious Anaphylaxis
Postmarketing Abdominal pain, rash
Most common (>=10%) Injection site reactions, upper respiratory infections, headache, rash, dizziness, diarrhea, myalgia.
Less common Hypersensitivity, increased aspartate transaminase, increased alanine transaminase.
Pharmacology
Recombinant C1 esterase inhibitor (C1INH) that regulates the complement and contact system pathways by irreversibly binding target proteases (activated C1s, kallikrein, factor XIIa, factor XIa), restoring functional C1INH activity and suppressing the bradykinin-mediated vascular permeability increases that underlie HAE attacks.
Plasma kallikrein inhibitor; lanadelumab-flyo is a fully human IgG1/kappa monoclonal antibody that binds and inhibits plasma kallikrein, reducing cleavage of high-molecular-weight kininogen and excess bradykinin generation that causes increased vascular permeability and angioedema attacks in HAE patients with C1-inhibitor deficiency or dysfunction.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ruconest
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (3/12) · Qty limit (9/12)
Takhzyro
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Ruconest
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (4/8)
Takhzyro
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Ruconest
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Takhzyro
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RuconestView full Ruconest profile
TakhzyroView full Takhzyro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.